20/12/2014 12:15:00 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
12/17/201410:00AMBWBristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015. During a conference call at 9 a.m. EST on January 27, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general... More...>>
12/12/20146:22PMDJNDanone Committed to All Business Units -- 2nd Update
By Ruth Bender PARIS-- Danone SA said it is keeping its medical-nutrition business, after months of talks with potential buyers that gave rise to speculation that the French yogurt maker could be embarking on a bigger deal in its quest to revive growth. The owner of Activia yogurt and Aptamil baby formula on Friday said... More...>>
12/12/20145:06AMDJNDanone Committed to All Business Units -- Update
By Ruth Bender PARIS-- Danone SA said it is keeping its medical-nutrition business, after months of talks with potential buyers that gave rise to speculation that the French yogurt maker could be embarking on a bigger deal in its quest to revive growth. The owner of Activia yogurt and Aptamil baby formula on Friday said... More...>>
12/10/20146:00AMBWOno Pharmaceutical, Bristol-Myers Squibb & Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo ...
Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company (NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune... More...>>
12/09/20144:30PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on February 2, 2015, to stockholders of record at the close of business on January... More...>>
12/08/20147:39PMDJNU.S. Files Suit Against Deutsche Bank -- 2nd Update
By Saabira Chaudhuri And Christopher M. Matthews The Justice Department has sued Deutsche Bank AG over allegations of tax fraud, saying the German lender owes taxes and penalties amounting to more than $190 million over a transaction that took place more than a decade ago. The U.S. Attorney for the Southern District of... More...>>
12/08/20147:08PMDJNU.S. Files Suit Against Deutsche Bank -- Update
By Saabira Chaudhuri The Justice Department has sued Deutsche Bank AG over allegations of tax fraud, saying the German lender owes taxes amounting to more than $190 million. The U.S. Attorney for the Southern District of New York, Preet Bharara, in a civil suit filed Monday in Manhattan federal court alleged that Deutsche... More...>>
12/08/20141:30PMBWAnticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subj...
Data Presented Today at the 56th Annual American Society of Hematology (ASH) Meeting Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates... More...>>
12/06/20141:00PMBWOpdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma
Results support Opdivo Breakthrough Therapy Designation granted by FDA for the treatment of patients with Hodgkin Lymphoma after failure of autologous stem cell transplant and brentuximab Safety and tolerability results, a primary objective in the study, were consistent with other Opdivo trials Results from another arm... More...>>
12/03/20149:00AMBWBristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients wit...
Grants align with World Health Organization strategy to provide screening and care for vulnerable populations and regional efforts to raise viral hepatitis prevention awareness among care providers The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts... More...>>
12/01/20149:00AMBWBristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Million in New Grants to Strengthen HIV-Related Servic...
Grants from landmark Secure the Future initiative target adolescents, the elderly and HIV patients with female cancers or tuberculosis in Kenya, Zimbabwe, South Africa, Swaziland and Lesotho The Bristol-Myers Squibb Foundation today marked World AIDS Day by announcing 12 new grants totaling $1.47 million that focus on... More...>>
11/26/201411:34AMBWBristol-Myers Squibb Receives Complete Response Letter from U.S. Food & Drug Administration for Daclatasvir, an Investigation...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir... More...>>
11/24/20149:57AMDJNBristol-Myers, Five Prime to Collaborate on Immunotherapy
By Tess Stynes Bristol-Myers Squibb Co. (BMY) and Five Prime Therapeutics Inc. (FPRX) agreed to collaborate on potential combinations of their investigational immunotherapies to treat six types of cancers. Five Prime shares rose 14.3% to $18 in recent premarket trading. Immunotherapy drugs work by unleashing the body's... More...>>
11/24/20148:59AMBWBristol-Myers Squibb & Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Inves...
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed... More...>>
11/19/20145:59AMPRNCAOpdivo (nivolumab), un nouvel inhibiteur du point de contrôle immunitaire PD-1, est le premier à avoir produit un bienfait ...
Opdivo (nivolumab), un nouvel inhibiteur du point de contrôle immunitaire PD-1, est le premier à avoir produit un bienfait sur le plan de la survie lors d'un essai de phase III sur le mélanome au stade avancé jamais traité Canada NewsWire MONTRÉAL, le 19 nov. 2014 Les résultats de l'étude... More...>>
11/19/20145:59AMPRNCANew PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment n...
New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma Canada NewsWire MONTREAL, Nov. 19, 2014 Results of study conducted in Canada, Australia and Europe presented at Society for Melanoma Research and published in The New... More...>>
11/18/20142:00AMBWAllied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Inn...
Synergy Partners offers significant experience in drug discovery and development. Areas of specialty include R&D strategy, medicinal chemistry, pharmacology, metabolism, drug safety and clinical development. Synergy Partners will provide strategic advice and scientific support to Allied-Bristol Life Sciences’ R&D... More...>>
11/17/20148:00AMBWAnalyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citru...
First-line therapy with Orencia in combination with MTX resulted in patients with early RA achieving significantly higher rates of stringent measures of remission, including 37 percent of patients achieving Boolean-defined remission and 42 percent of patients achieving CDAI- and SDAI-defined remission at 12 months versus... More...>>
11/16/20143:45AMBWStudy Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Che...
Opdivo demonstrated superior overall survival vs. dacarbazine with a one-year survival rate of 73% vs. 42% and a 58% decrease in the risk of death (Hazard Ratio [HR] = 0.42, P<0.0001) Objective response rate was significantly higher for Opdivo than dacarbazine (40% vs.14%), including a higher percentage of complete... More...>>
11/14/20146:00AMBWBristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland
State-of-the-art facility will produce multiple therapies for the company’s growing biologics portfolio Significant investment builds on 50 years of company’s manufacturing history in Ireland 350 to 400 manufacturing jobs and about 1,000 construction jobs expected to be created Bristol-Myers Squibb Company (NYSE:BMY... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy141220 12:15